US FDA Approves First Blood Test to Help Diagnose Alzheimer’s Disease

Washington: FDA Approves First Blood Test to Aid Alzheimer’s Diagnosis

The U.S. Food and Drug Administration (FDA) has approved the first-ever blood test to assist in diagnosing Alzheimer’s disease. Developed by Fujirebio Diagnostics, the test is intended for individuals aged 55 and older who are already showing symptoms of the condition. It detects levels of specific proteins associated with amyloid plaques in the brain, a key indicator of Alzheimer’s.

Experts say the test offers a simpler, less invasive alternative to traditional diagnostic methods like PET scans and spinal taps, potentially enabling earlier detection and treatment. While not a standalone diagnostic tool, it is expected to significantly speed up the diagnostic process when used alongside other clinical evaluations.

This approval marks a major step forward for the millions affected by Alzheimer’s disease, offering new hope for timely and effective intervention.